DUAL ANTIPLATELET THERAPY IN THE REAL CLINICAL PRACTICE
https://doi.org/10.20996/1819-6446-2014-10-5-500-504
Abstract
Aim. To evaluate an adequacy of dual antiplatelet therapy (DAPT) in patients with acute coronary syndrome (ACS) with ST segment elevation and bare metal stent implantation after hospital discharge.
Material and methods. 311 patients with ACS with ST segment elevation were included into the study. All of them underwent percutaneous coronary intervention with bare metal stent implantation. The information was obtained by the telephone survey.
Results. 54.5% of patients received DAPT during 12 months. 43.8% of patients also received combination of clopidogrel and acetylsalicylic acid, but changed medicinal products of clopidogrel due to different reasons. 1.7% of patients received acetylsalicylic acid only.
Conclusion. More than 50% of patients received recommended DAPT at that they preferred generic drugs of clopidogrel original one.
About the Authors
G. N. Guseva
Samara Region Clinical Cardiology Hospital
Russian Federation
Russian Federation
Aerodromnaya ul. 43, Samara, 443070 Russia
T. V. Pavlova
Samara Region Clinical Cardiology Hospital, Samara State Medical University
Russian Federation
Russian Federation
Aerodromnaya ul. 43, Samara, 443070 Russia
Chapaevskaya ul. 89, Samara, 443099 Russia
I. L. Voronova
Samara State Medical University
Russian Federation
Chapaevskaya ul. 89, Samara, 443099 Russia
Russian Federation
Chapaevskaya ul. 89, Samara, 443099 Russia
S. M. Chohlunov
Samara Region Clinical Cardiology Hospital, Samara State Medical University
Russian Federation
Russian Federation
Aerodromnaya ul. 43, Samara, 443070 Russia
Chapaevskaya ul. 89, Samara, 443099 Russia
References
1. National guidelines for the diagnosis and treatment of patients with acute myocardial infarction with ST-segment elevation ECG. Kardiovaskulyarnaya Terapiya i Profilaktika 2007; 6 (8) suppl 1: 1-48. Russian (Национальные рекомендации по диагностике и лечению больных острым инфарктом мио-карда с подъемом сегмента ST ЭКГ. Кардиоваскулярная Терапия и Профилактика 2007; 6 (8) При-ложение 1: 1-48).
2. Myocardial revascularization. Guidelines ESC/EACT. Eur Heart J 2010; 31: 2501-55.
3. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA Guideline for the Management of STElevation Myocardial Infarction. A Report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 61: e78-e140.
4. Metba S., Yusuf S., Peters R. et al. Effects of pretreatment with Clopidogrel and aspirin fillowed lingterm therapy in patients undergoing percutaneous coronary intervention the PCI CURE study. Lancet 2001; 358: 527-33.
5. Paters R., Metba S., Fox K. et al. Effect of aspirin dose when used alone or in combination with Clopidogrel in patients with acute coronary syndromes: observation from CURE Study. Circulation 2003; 108: 1682-7.
6. Duplyakov DV, Hohlunov, SM, AA Tuhbatova et al. Acute coronary syndrome-segment elevation ST: the possibility of the hospital register. Kardiologiya i Serdechno-sosudistaya Khirurgiya 2010; (4): 27-31. Russian (Дупляков Д.В., Хохлунов, С.М., Тухбатова А.А. с соавт. Острый коронарный синдром с подъемом сегмента ST: возможности госпитального регистра. Кардиология и Сердечно-сосудистая Хирургия 2010;(4):27-31).
7. Boggon R, van Staa TP, Timmis A. et al. Clopidogrel discontinuation after acute coronary syndromes: frequency, predictors and associations with death and myocardial infarction--a hospital registry-primary care linked cohort (MINAP-GPRD). Eur Heart J 2011; 32 (19): 2376-86.
8. Martsevich SYu, Voronina VP, Ginsburg ML et al. Contemporary antiplatelet therapy in patients at high risk of thrombotic events and actual clinical practice. Ration Pharmacother Cardiol 2012; 8 (8): 163-7. Russian (Марцевич С.Ю., Воронина В.П., Гинзбург М.Л. и др. Современная терапия анти-агрегантами больных с высоким риском тромбообразования и реальная клиническая практи-ка. Рациональная Фармакотерапи в Кардиологии 2012; 8(8): 163-7).
9. Martsevich SYu, Ginsburg ML, Malysheva AM, et al. Modern antiplatelet therapy in patients with ischemic heart disease with a high risk of thrombotic complications. These evidence-based medicine and practice. Ration Pharmacother Cardiol 2011; 7 (3): 319-22 . Russian (Марцевич С.Ю., Гинзбург М.Л., Малышева А.М., и др. Современная терапия антиагрегантами больных ишемической болезнью сердца с высоким риском тромботических осложнений. Данные доказательной медицины и ре-альная практика. Рациональная Фармакотерапи в Кардиологии 2011;7(3): 319-22).
10. Martsevich SYu, Kutishenko NP, Ginsburg ML, et al. Antiplatelet therapy in patients at high risk of thrombotic complications: the problem of the efficacy, safety and commitment. Klinitsist 2011; (2): 72-9. Russian (Марцевич С.Ю., Кутишенко Н.П., Гинзбург М.Л., и др. Антиагрегантная терапия у боль-ных с высоким риском развития тромботических осложнений: проблема эффективности, без-опасности и приверженности. Клиницист 2011; (2): 72-9).
11. Gaisenok OV. On the role of modern antiplatelet therapy in the prevention of atherothrombotic events: the place of clopidogrel and of generic drugs. Ration Pharmacother Cardiol 2011; 7 (1): 89-93. Russian (Гайсёнок О.В. О роли современной антитромбоцитарной терапии в профилактике ате-ротромбоза: место клопидогрела и его дженерических препаратов. Рациональная Фармако-терапия в Кардиологии 2011;7(1): 89-93).
12. Yavelov IS. Clopidogrel: where the boundary known and unexplored? Klinicheskaya Farmakologiya i Terapiya 2012; 21 (1): 48-53. Russian (Явелов И.С. Препараты клопидогрела: где проходит гра-ница известного и неизученного? Клиническая Фармакология и Терапия 2012; 21 (1): 48-53).
13. Trukhan DI, Pavlova TV, Viktorova IA. Optimization of non-pharmacological and pharmacological effects on pathogenetic factors and the development of arterial hypertension in the new research educational health program PERSPEKTIVA. Spravochnik Poliklinicheskogo Vracha 2012; (11); 18-22. Russian (Трухан Д.И., Павлова Т.В., Викторова И.А. Оптимизация немедикаментозного и ме-дикаментозного воздействия на патогенетические факторы развития и течения артериальной гипертензии в рамках новой научно-исследовательской образовательной оздоровительной про-граммы ПЕРСПЕКТИВА. Справочник Поликлинического Врача 2012; (11); 18-22).
Review
For citations:
Guseva G.N., Pavlova T.V., Voronova I.L., Chohlunov S.M. DUAL ANTIPLATELET THERAPY IN THE REAL CLINICAL PRACTICE. Rational Pharmacotherapy in Cardiology. 2014;10(5):500-504. (In Russ.) https://doi.org/10.20996/1819-6446-2014-10-5-500-504
Views:
754
.jpg)
Email this article 